Related Experiment Videos
Polyvalent DNA vaccines with bidirectional promoters.
M Kwissa1, J Unsinger, R Schirmbeck
1Institute for Medical Microbiology, University of Ulm, Germany.
Journal of Molecular Medicine (Berlin, Germany)
|January 5, 2001
Summary
Synthetic polyvalent plasmids efficiently prime hepatitis B virus (HBV) immunity. This DNA vaccination approach shows potential, with even low antigen expression levels inducing a robust immune response.
Area of Science:
- Immunology
- Molecular Biology
- Vaccinology
Background:
- Hepatitis B virus (HBV) infection poses a significant global health challenge.
- Developing effective DNA vaccines requires optimized antigen expression and immune stimulation.
Purpose of the Study:
- To evaluate a synthetic bidirectional promoter system for coexpressing hepatitis B surface antigen (HBsAg) and core antigen (HBcAg).
- To assess the efficacy of this system in DNA vaccination for inducing HBV-specific immunity in vitro and in vivo.
Main Methods:
- Coexpression of HBsAg and HBcAg using a synthetic bidirectional promoter with a tetracycline-inactivated transactivator (tTA).
- Evaluation in established cell lines and through intramuscular/intradermal DNA injection in mice.
- Measurement of in vitro antigen expression and in vivo humoral and cellular immune responses.
Main Results:
- Successful autoregulation of antigen expression was achieved in cultured cells.
- DNA vaccination efficiently primed HBV-specific immunity, including humoral and cellular responses.
- Immunogenic antigen concentrations were observed even without the transactivator, suggesting low expression suffices for immune priming.
Conclusions:
- Synthetic polyvalent plasmids are effective for DNA vaccination against HBV.
- The bidirectional promoter system allows flexible coexpression strategies, enhancing stable immunity.
- This study highlights the potential of synthetic constructs for developing next-generation HBV vaccines.